Angels Catwalk for SickKids
Transplant Heroes

Dear Transplant Recipients, Transplant Recipient Families, Organ Donors, Donor Families and Registered Donors,

We will be forever grateful to our heros that gave us life. For those that donated an organ to a loved one or anonymously through a living or deceased donation; they have given us a second chance, the gift of life, and have become our heros. The Donor Catwalk was established at the 2013 Angels Catwalk for SickKids to raise awareness for organ and tissue donation, honour our donors, celebrate life and support transplant research. Donors and organ recipients fundraised for the chance to walk the runway. It was one of the many highlights of the night. Over the past three years donor teams have raised an amazing $91,000 for many research initiatives!

To register as a
Donor Catwalk team,

What is involved?

Registered Donor Catwalk teams, consisting of 1 to 3 individuals, agree to fundraise for Ashley’s Angels in support of transplant research at SickKids. The 2016 teams raised over $24,000! Stay tuned for our 2017 research project!


  • All teams, regardless of fundraising amount, will contribute to supporting the 2017 research project.
  • All teams that raise $1,000 or more will receive a total of 4 complimentary tickets per team to the Angels Catwalk for SickKids on November 16, 2017.
  • Each team that raises a minimum of $1,500 will have the opportunity to walk the runway all together as a group in the Angels Catwalk for SickKids on November 16, 2017.
  • The top 3 qualifying fundraising Donor Catwalk teams will have the opportunity to walk the runway individually at the event and be treated like a high fashion model, with professional hair and makeup experiences.
  • The top fundraising team will have the opportunity to walk the runway at the event with a spotlight on their story, be treated like a high fashion model, with professional hair and makeup experiences.

Stay tuned for other fundraising incentive levels and prizing!

Fundraising to qualify for the Donor Catwalk will close
on Monday, November 13th at 4 p.m.

Register today, as a Donor Catwalk team you will help bring awareness to organ and tissue donation, honour your donor, celebrate life and support transplant research!


Cheryl Brandon & Ashley Logan

Cheryl & Ashley


Rob's Angels

Rob's Angels


Liver Givers

Liver Givers


Team SuperRy

Team SuperRy


Team Giving is Receiving

Giving is Receiving


Team Donorthoners

Donorthoners Ashley's Angels In Support of SickKids
An evening of entertainment, fashion and fundraising


This is a study of children with a condition referred to as post-transplant lymphoproliferative disorder (PTLD). PTLD usually develops as a result of primary (new-onset) infection caused by the Epstein-Barr virus (EBV). This is the same virus that causes mononucleosis, which is otherwise known as kissing disease. EBV can cause a wide range of problems in people who get infected. However, the virus often infects white blood cells, causing the cells to multiply out of control in some individuals with weakened immune systems. This change in the white blood cells often leads to PTLD which can behave like a cancer-like condition in some patients. Transplant patients have weakened immune systems and as such may develop PTLD. Doctors need more information to help them better understand the reasons why some individuals do well with PTLD, while others have extremely severe disease. Some experts refer to the latter as “extreme phenotypes”. This information will help us to design the best tailor-made treatments for those at high risk of having the severe forms of PTLD.

We will study organ transplant recipients, with healthy individuals as a comparison group. We will use a procedure called exome sequencing. This procedure will allow us to determine the sequence patterns of special regions of certain genes that influence how well a person’s immune system is able to fight off the bad consequences of PTLD. The sequencing will be done on DNA samples obtained from the study participants.

In addition to testing the above genes, we will be testing for different strains of the virus by examining the gene sequences of EBV. This will help us to determine whether infection by certain strains of EBV increase the risk of getting PTLD.

The study will be done over 12 months. In the end we hope to be able to identify gene markers that tell us who is at the greatest risk of PTLD, so that we can identify them and put them on the appropriate treatment. The study will yield exciting new information that will improve survival after transplantation. There is nothing more devastating than seeing a child’s life being saved by organ transplantation and then only to be taken away by the development of PTLD.